Pramana

HARNESSING THE POWER OF GPCRS

A Novel Approach to Therapeutic Development for Metabolic Disorders

Improving lives targeting GPCRs and unmet needs in Metabolic Disease

The opportunity for an Oral Preventative Treatment for Hypoglycemia is just one of many areas of high unmet medical need associated with Metabolic Disorders. We are committed to addressing this.

About us

GPCR Centric

We are a GPCR centric Biopharmaceutical Company advancing a broad pipeline of biologic drug candidates. Our library of Novel potent GPCR agonists was discovered and optimized in-house.

Pipeline

Improving lives targeting GPCRs

Pramana’s Lead Compound, PRM A has shown significant and differentiating glucagon response.

The Market

Untapped Opportunity

The need for an oral preventative treatment for Hypoglycemia is just one of many areas of high unnmet medical need associated with Diabetes.

The Team

Driving Success

We founded Pramana with the vision to enable a scientific team that has a formidable track record of success in drug discovery and development.

Platform

Diabetes & Metabolic Disorders

Overseen by a world class scientific team, Pramana has utilized their expertise in the development of its highly potent, selective small molecules.

490,000,000,000

Dollars in Global Healthcare Expenditures of Diabetes by 2030

100,000,000

People affected by hypoglycemia right now

537,000,000

People currently live with diabetes

1,000,000,000+

People will suffer from diabetes by 2050

The unmet opportunity - Pramana's commitment

The opportunity for an Oral Preventative Treatment for Hypoglycemia is just one of many areas of high unmet medical need associated with Metabolic Disorders. We are committed to addressing this.

The name Pramana is derived from Sanskrit; it means "Proof and Means of Knowledge". It's foundation is based on achieving excellence through expertise.

The opportunity for an Oral Preventative Treatment for Hypoglycemia is just one of many areas of high unmet medical need associated with Metabolic Disorders. We are committed to addressing this.